FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or...
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel...
PARIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene...
Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks,...
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate...
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)...
First commercially available products using AMSilk’s biotech silk protein yarnsDemonstrating a scalable, low impact alternative to conventional silk within luxury...
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the...
Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine....
Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine....
Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective...
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide...
APOLLO BEACH, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution...
Since 2018, more than $40 million has been granted to support outstanding cancer research projects by early-career scientistsNEW YORK, Jan....
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan....
SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial...
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to...
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key...
The companies have a shared vision to make medical imaging AI simpler, faster and more human Konica Minolta Healthcare and...
Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes...